Ann Arbor, Michigan-based Zomedica Corp. (NYSE American: ZOM / OTCQB: ZOMDF) has unveiled an expanded global operational strategy update focused on accelerating the adoption of its point-of-care (POC) diagnostic and therapeutic platforms for companion animals and horses across veterinary practices worldwide.
The strategic roadmap establishes a unified operational, commercial, and manufacturing framework aimed at capturing an estimated $2+ billion total addressable market (TAM) across equine and companion animal healthcare. Driven by strong multi-product adoption and rapid international expansion in Europe and the UK, Zomedica is positioning its ecosystem to deliver immediate clinical answers, streamline veterinary practice workflows, and maximize practice profitability.
Strategic Core: The Five Pillars Framework
At the centerpiece of Zomedica’s operational update is its proprietary Five Pillars Framework, which governs all internal R&D, product integration, commercial execution, and M&A activities. Every platform entering the company’s portfolio must deliver verifiable performance across five criteria:
-
Quality of Clinical Care: Delivering rapid, highly accurate, in-clinic answers and regenerative therapies to advance patient outcomes.
-
Pet Parent Satisfaction: Offering non-invasive, low-stress, and rapid diagnostic/therapeutic experiences that build client trust.
-
Veterinary Workflow Efficiency: Closing the time gap between clinical questions and treatments while optimizing clinic staff time.
-
Practice Cash Flow: Eliminating high upfront capital costs for key diagnostic and therapeutic hardware.
-
Practice Profitability: Generating immediate, sustainable, consumable-driven revenue streams for veterinary clinics.
Expanding the Point-of-Care Diagnostic & Therapeutic Portfolio
Zomedica’s integrated ecosystem spans complementary diagnostic technologies and non-pharmaceutical therapeutic devices.
Platform Category |
Product |
Core Technology & Clinical Utility |
Target Markets |
POC Diagnostics |
TRUFORMA® |
Bulk Acoustic Wave (BAW) sensor technology delivering central-lab quality endocrine, thyroid, and adrenal testing in-clinic in minutes. Features a strategic collaboration with Boehringer Ingelheim for equine endocrine testing. |
Canine, Feline, Equine |
Digital Cytology |
TRUVIEW™ |
Automated liquid-lens slide scanning coupled with AI-driven preliminary interpretation and rapid board-certified pathologist review. |
Companion Animal |
Shock Wave Therapy |
PulseVet® |
High-energy focused acoustic shock wave system accelerating musculoskeletal healing, soft tissue repair, and osteoarthritis recovery. |
Equine, Canine |
tPEMF Therapy |
Assisi Loop® Line |
Targeted Pulsed Electromagnetic Field (tPEMF™) technology reducing inflammation, relieving pain, and accelerating tissue healing in-clinic or at home. |
Companion Animal, Hospice |
Patient Monitoring |
VETGuardian PLUS™ |
Contactless, zero-touch continuous vital sign monitoring (heart rate, respiration) for post-operative and ICU recovery. |
Companion Animal |
Surgical Hemostasis |
VETIGEL® |
Plant-based hemostatic gel stopping arterial and venous surgical bleeding in under 10 seconds. |
Surgical / Emergency |
Scalable In-House Manufacturing & Operational Infrastructure
To maintain margins and ensure clinical precision across its high-mix product lines, Zomedica has operationalized a dual-facility manufacturing model in Georgia and Minnesota.
-
High-Mix & Rapid Iteration: Specialized engineering teams handle optics assembly, camera alignment, illumination calibration, and precision motion testing for advanced systems like TRUVIEW and VETGuardian.
-
High-Throughput Production: Dedicated volume manufacturing facilities in Plymouth produce consumable acoustic transducers, microfluidic cartridges, and tPEMF devices under ISO-compliant quality systems.
-
Supply Chain Efficiency: Cross-trained assembly technicians and consolidated component sourcing mitigate supply chain risks while supporting high gross margins.
Commercial Execution & Global Growth Trajectory
Zomedica’s operational strategy relies on a combined direct sales force and professional services team that transitions single-product users into multi-platform partners
Key Commercial Highlights:
-
International Expansion: Accelerating deployment in the United Kingdom, European Union, and Latin American markets through expanded distributor partnerships.
-
Strategic Partnerships: Expanding clinical capabilities through alliances, such as the equine diagnostic partnership with Boehringer Ingelheim and “Fear Free®” product designations for Assisi therapy devices.
-
Consumable Revenue Engine: Capitalizing on recurring revenue from diagnostic cartridges, shock wave trode refills, and software/monitoring fees.
Market Outlook & Path to Profitability
With record quarterly revenue growth exceeding 35% year-over-year and a solid liquidity position of over $40 million, Zomedica’s operational strategy update underlines a clear pathway toward sustained profitability. By combining point-of-care diagnostics with non-invasive therapeutics, Zomedica addresses critical labor and diagnostic delay challenges facing modern veterinary practices globally.
